메뉴 건너뛰기




Volumn 20, Issue 2, 2018, Pages 458-462

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials

Author keywords

meta analysis; SGLT2 inhibitor; type 2 diabetes; uric acid

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; TOFOGLIFLOZIN; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85040723946     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13101     Document Type: Article
Times cited : (268)

References (21)
  • 1
    • 84890077367 scopus 로고    scopus 로고
    • Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China
    • Wang J, Chen RP, Lei L, et al. Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China. Asia Pac J Clin Nutr. 2013;22:590–598.
    • (2013) Asia Pac J Clin Nutr , vol.22 , pp. 590-598
    • Wang, J.1    Chen, R.P.2    Lei, L.3
  • 2
    • 85008612450 scopus 로고    scopus 로고
    • Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review
    • Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8:537–548.
    • (2017) J Adv Res , vol.8 , pp. 537-548
    • Sharaf El Din, U.A.A.1    Salem, M.M.2    Abdulazim, D.O.3
  • 3
    • 85015266193 scopus 로고    scopus 로고
    • Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
    • Desai M, Yavin Y, Balis D, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19:897–900.
    • (2017) Diabetes Obes Metab , vol.19 , pp. 897-900
    • Desai, M.1    Yavin, Y.2    Balis, D.3
  • 4
    • 58149357463 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
    • Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11:79–88.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 79-88
    • Idris, I.1    Donnelly, R.2
  • 5
    • 85021986989 scopus 로고    scopus 로고
    • Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
    • Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;1–5.
    • (2017) Diabetes Obes Metab , pp. 1-5
    • Chilton, R.1    Tikkanen, I.2    Hehnke, U.3    Woerle, H.J.4    Johansen, O.E.5
  • 6
    • 84969784577 scopus 로고    scopus 로고
    • Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease
    • Leiter LA, Cefalu WT, de Bruin TW, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18:766–774.
    • (2016) Diabetes Obes Metab , vol.18 , pp. 766-774
    • Leiter, L.A.1    Cefalu, W.T.2    de Bruin, T.W.3
  • 7
    • 84969915634 scopus 로고    scopus 로고
    • Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
    • Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
    • (2016) Diabetes Obes Metab , vol.18 , pp. 783-794
    • Zaccardi, F.1    Webb, D.R.2    Htike, Z.Z.3    Youssef, D.4    Khunti, K.5    Davies, M.J.6
  • 8
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 9
    • 85021244090 scopus 로고    scopus 로고
    • Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
    • Xu L-B, Li Y, Lang J-X, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ. 2017;5:e3405.
    • (2017) PeerJ , vol.5
    • Xu, L.-B.1    Li, Y.2    Lang, J.-X.3
  • 11
    • 85047692188 scopus 로고
    • Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
    • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.
    • (1995) JAMA , vol.273 , pp. 408-412
    • Schulz, K.F.1    Chalmers, I.2    Hayes, R.J.3    Altman, D.G.4
  • 12
    • 0037098199 scopus 로고    scopus 로고
    • Quantifying heterogeneity in a meta-analysis
    • Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
    • (2002) Stat Med , vol.21 , pp. 1539-1558
    • Higgins, J.P.1    Thompson, S.G.2
  • 13
    • 84895484977 scopus 로고    scopus 로고
    • Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    • Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204–221.
    • (2014) Diabetes Metab Res Rev , vol.30 , pp. 204-221
    • Zhang, M.1    Zhang, L.2    Wu, B.3    Song, H.4    An, Z.5    Li, S.6
  • 14
    • 84860183617 scopus 로고    scopus 로고
    • A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials
    • Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
    • (2012) Ann Med , vol.44 , pp. 375-393
    • Musso, G.1    Gambino, R.2    Cassader, M.3    Pagano, G.4
  • 15
    • 84938924986 scopus 로고    scopus 로고
    • Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis
    • Fan Y, Wei F, Lang Y, Wang S. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens. 2015;33:681–688.
    • (2015) J Hypertens , vol.33 , pp. 681-688
    • Fan, Y.1    Wei, F.2    Lang, Y.3    Wang, S.4
  • 16
    • 84975707191 scopus 로고    scopus 로고
    • Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis
    • Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76:947–956.
    • (2016) Drugs , vol.76 , pp. 947-956
    • Derosa, G.1    Maffioli, P.2    Reiner, Z.3    Simental-Mendia, L.E.4    Sahebkar, A.5
  • 17
    • 84942872229 scopus 로고    scopus 로고
    • Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials
    • Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
    • (2015) Pharmacol Res , vol.102 , pp. 63-70
    • Derosa, G.1    Maffioli, P.2    Sahebkar, A.3
  • 18
    • 5344244028 scopus 로고    scopus 로고
    • Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
    • Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148:635–640.
    • (2004) Am Heart J , vol.148 , pp. 635-640
    • Milionis, H.J.1    Kakafika, A.I.2    Tsouli, S.G.3
  • 20
    • 84920971105 scopus 로고    scopus 로고
    • Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
    • Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308:F77–F83.
    • (2015) Am J Physiol Renal Physiol , vol.308 , pp. F77-F83
    • Lytvyn, Y.1    Skrtic, M.2    Yang, G.K.3    Yip, P.M.4    Perkins, B.A.5    Cherney, D.Z.6
  • 21
    • 84908555003 scopus 로고    scopus 로고
    • SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
    • Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.
    • (2014) Biopharm Drug Dispos , vol.35 , pp. 391-404
    • Chino, Y.1    Samukawa, Y.2    Sakai, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.